SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
MGI Pharma MOGN New patents, anti cancer
An SI Board Since June 1996
Posts SubjectMarks Bans Symbol
1826 45 0 MOGN
Emcee:  Mark Oliver Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
1526Update on Oral Mucositis: MASCC/ISOO 16th International Symposium [Some backgroIcebrg-9/10/2004
1525SuperGen Skepticism No Longer Warranted By Adam Feuerstein Senior Writer 9/8/20Icebrg-9/8/2004
1524MGI Pharma upgraded to "outperform" - update Tuesday, September 07, 2Icebrg-9/7/2004
1523Irofulven Cytotoxicity Depends on Transcription-Coupled Nucleotide Excision RepaIcebrg-9/6/2004
1522ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: a randomIcebrg-9/4/2004
1521MGI Pharma upgraded to "outperform" Thursday, September 02, 2004 12:1Icebrg-9/2/2004
1520MGI Pharma "outperform" Thursday, September 02, 2004 8:33:15 AM ET RoIcebrg-9/2/2004
1519MGI's 'Great Day': Deal To Market Dacogen, Two Companies Bought By Icebrg-9/2/2004
1518MGI PHARMA and SuperGen Announce Signing of a Worldwide License Agreement for DaIcebrg-9/1/2004
1517MGI PHARMA to Acquire Aesgen -- Saforis For Oral Mucositis Bolsters MGI's OnIcebrg-9/1/2004
1516MGI PHARMA to Acquire Zycos Wednesday September 1, 6:00 am ET Pivotal Phase 3 PrIcebrg-9/1/2004
1515MGI Pharma "outperform" Monday, August 16, 2004 8:22:40 AM ET Robert Icebrg-8/29/2004
1514MGI Pharma "market outperform," target price reduced Wednesday, AugusIcebrg-8/29/2004
1513A phase II trial of 6-hydroxymethylacylfulvene (MGI-114, irofulven) in patients Icebrg-8/12/2004
1512MGI Pharma "outperform" Wednesday, July 28, 2004 8:59:28 AM ET RobertIcebrg-7/28/2004
1511This is what I get from Merrill: <i>MGI Pharma (MOGN; $25.95; C-1-9): A 3tom pope-7/28/2004
1510Looks like this was a story written by someone who doesn't understand the buBiomaven-7/28/2004
1509Proposed Medicare cuts bode ill for MGI Pharma Staff and Wire Reports July 28, 2Icebrg-7/28/2004
1508Note the author Eddie Reed. He directed the Iro/Ovarian clinical work done by thseminole-7/27/2004
1507ATM-dependent CHK2 activation induced by anticancer agent, irofulven. J Biol ChIcebrg-7/23/2004
1506MGI Pharma "market outperform," estimates raised Friday, July 16, 200Icebrg-7/16/2004
1505MGI Pharma "outperform," estimates raised Thursday, July 15, 2004 9:1Icebrg-7/15/2004
1504MGI Pharma "outperform," estimates raised Thursday, June 17, 2004 3:2Icebrg-6/17/2004
1503MGI Pharma "outperform" Friday, June 11, 2004 7:12:27 AM ET Robert W.Icebrg-6/11/2004
1502Sorry, guys and gals, but MOGN cut in half pre-market..... <i>Splits Calescaram(o)uche-6/10/2004
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News